Aleali Maryam Sadat, Mahapatro Abinash, Maddineni Gautam, Paladiya Ruchir, Jeanty Herby, Mohanty Elan, Mirchandani Mohit, Jahanshahi Ali, Devulapally Pavan, Alizadehasl Azin, Tariq Muhammad Daoud, Hosseini Jebelli Seyedeh Fatemeh, Aliabadi Azam Yalameh, Hashemi Seyyed Mohammad, Amini-Salehi Ehsan
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Hi-Tech Medical College and Hospital, Rourkela, Odisha, India.
Ann Med Surg (Lond). 2025 Mar 7;87(4):2263-2277. doi: 10.1097/MS9.0000000000003140. eCollection 2025 Apr.
Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome's role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS.
A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients.
The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: -0.22; 95% CI: -0.35 to -0.09; < 0.01) and waist circumference (WC) (SMD: -0.47; 95% CI: -0.80 to -0.15; < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: -0.30; 95% CI: -0.64 to 0.02; = 0.06), body fat percentage (SMD: -0.29; 95% CI: -0.62 to 0.03; = 0.07), waist-to-hip ratio (SMD: -0.09; 95% CI: -0.46 to 0.28; = 0.63), and weight (SMD: -0.06; 95% CI: -0.21 to 0.08; = 0.37).
Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions' therapeutic potential.
代谢综合征（MetS）是一种以一系列代谢风险因素为特征的复杂病症。近期研究凸显了肠道微生物群在代谢调节中的作用，这表明通过益生菌、益生元及合生元进行调节可能为管理代谢综合征提供一种新方法。本伞状综述旨在整合现有荟萃分析的见解，以探究肠道微生物群的变化如何影响代谢综合征患者的关键身体测量指标。
对PubMed、Scopus和Web of Science数据库进行系统检索，以确定评估益生菌、益生元或合生元对代谢综合征患者人体测量指标影响的荟萃分析。
结果表明，微生物疗法可显著降低体重指数（BMI）（标准化均数差：-0.22；95%置信区间：-0.35至-0.09；P<0.01）和腰围（WC）（标准化均数差：-0.47；95%置信区间：-0.80至-0.15；P<0.01）。然而，微生物疗法对体脂量（标准化均数差：-0.30；95%置信区间：-0.64至0.02；P = 0.06）、体脂百分比（标准化均数差：-0.29；95%置信区间：-0.62至0.03；P = 0.07）、腰臀比（标准化均数差：-0.09；95%置信区间：-0.46至0.28；P = 0.63）和体重（标准化均数差：-0.06；95%置信区间：-0.21至0.08；P = 0.37）没有显著影响。
主要通过益生菌和合生元进行的肠道微生物调节在降低代谢综合征患者的BMI和WC方面显示出前景。然而，其对其他人体测量指标的影响仍不确定，需要进一步开展高质量研究以充分了解微生物干预的治疗潜力。
